# Alamandine: MrgD-Receptor Peptide of the Alternative Renin-Angiotensin System — Research Profile
> Research Use Only (RUO). Alamandine is discussed here strictly as a laboratory research reagent and endogenous signaling peptide for in vitro and preclinical in vivo studies. Nothing below is medical, veterinary, therapeutic, or dosing guidance, and none of it describes human or animal use outside controlled research settings.
Alamandine is an endogenous heptapeptide of the alternative (protective) arm of the renin-angiotensin system (RAS) that signals through the Mas-related G-protein-coupled receptor type D (MrgD / MrgprD). Closely related to angiotensin-(1-7) but acting through a distinct receptor, alamandine has become an important research peptide for dissecting the counter-regulatory RAS axis that opposes the classical angiotensin II / AT1R pathway. This profile summarizes its molecular identity, biosynthesis, receptor pharmacology, and the experimental contexts in which it appears, with every claim tied to a verifiable primary-literature citation.
For the closely related peptides and the broader system, see the Peptides.SO angiotensin-(1-7) research profile and the angiotensin II / RAAS signaling profile.
The Renin-Angiotensin System: Two Opposing Arms
Modern RAS research recognizes two functionally opposed arms. The classical arm — angiotensin-converting enzyme (ACE) → angiotensin II → AT1 receptor — drives vasoconstriction, sodium retention, and pro-fibrotic signaling. The alternative (protective) arm — ACE2 → angiotensin-(1-7) → Mas receptor, together with alamandine → MrgD — generally opposes these actions. Reviews of this alternative RAS frame alamandine as a core effector of the protective axis, distinct from but parallel to angiotensin-(1-7) (Hypertension, 2024; Rev Cardiovasc Med, 2025). Understanding this duality is essential context for any laboratory study using alamandine as a tool peptide (Biomedicines, 2025).
Molecular Identity and Biosynthesis
Alamandine differs from angiotensin-(1-7) by a single, defining feature: an N-terminal alanine in place of aspartate, yielding the sequence often written as Ala1-angiotensin-(1-7). This single-residue change redirects the peptide from the Mas receptor to MrgD, illustrating how minimal primary-sequence variation in the RAS reroutes receptor selectivity. Alamandine can be generated through two converging routes: by decarboxylation of the N-terminal aspartate of angiotensin-(1-7), or via formation of angiotensin A followed by ACE2-mediated cleavage. The continued biochemical characterization of this axis remains active — recent work even identified alamandine-(1-5) as a further processed component of the system, extending the known peptide cascade (Circ Res, 2026).
Receptor Pharmacology: MrgD
The signature of alamandine is its action through MrgD (MrgprD), a class A GPCR distinct from the Mas receptor used by angiotensin-(1-7). This receptor assignment is the central pharmacological fact of alamandine biology and the basis for its use as a research probe. Genetic loss-of-function studies anchor the receptor's role: MrgD deficiency alters tissue physiology — for example promoting tubulointerstitial injury in model systems — demonstrating that the alamandine/MrgD axis is functionally non-redundant (Physiol Rep, 2026). Receptor-level studies across tissues, including localization and expression profiling of RAS receptors, situate MrgD within the broader receptor landscape and inform where alamandine signaling is expected to operate (Biomedicines, 2025).
For laboratory work, this means alamandine is most informative when paired with MrgD-selective antagonists or MrgD-null controls, so that observed effects can be attributed to the receptor rather than to overlap with the Mas or AT2 pathways.
Signaling and Experimental Readouts
Through MrgD, alamandine engages downstream cascades that generally produce vasoprotective and anti-fibrotic outputs in model systems. Commonly studied readouts and contexts include:
- •Vascular biology: alamandine has been reported to suppress vascular calcification through inhibition of ferroptosis in experimental models, a mechanism-level readout linking the peptide to cell-death pathways (Atherosclerosis, 2025).
- •Cardiac remodeling: studies report that alamandine attenuates hypoxia-induced atrial fibrosis and arrhythmogenic remodeling, used as a model of the protective axis opposing fibrosis (Cardiovasc Drugs Ther, 2025).
- •Angiogenesis: alamandine has been shown to inhibit pathological retinal neovascularization via the MrgD-mediated pathway, providing an ocular model of receptor-specific action (J Zhejiang Univ Sci B, 2025).
- •Bone biology: the alamandine/MrgprD axis has been characterized for antiresorptive effects in an experimental osteoporosis model, extending the peptide's research relevance beyond cardiovascular tissue (Calcif Tissue Int, 2026).
These citations describe laboratory and preclinical research models. They are included to map the research breadth of the alamandine/MrgD axis and do not constitute therapeutic claims; alamandine remains, in this profile, a reagent for controlled investigation only.
Alamandine versus Angiotensin-(1-7)
A recurring experimental theme is distinguishing alamandine from its near-twin, angiotensin-(1-7). The two peptides share most of their sequence and overlapping protective physiology but signal through different receptors — MrgD versus Mas. This makes them a natural matched pair for deconvolving which receptor drives a given protective effect: comparing alamandine with angiotensin-(1-7), and pairing each with its respective receptor antagonist, is a standard design for isolating MrgD- from Mas-mediated signaling. The broader scoping literature on alamandine's biological actions catalogs where the two axes converge and diverge (Biomedicines, 2025). For the Mas-receptor counterpart, see the Peptides.SO angiotensin-(1-7) profile; for the opposing classical arm, see the angiotensin II profile.
Handling and Assay Considerations for Researchers
- •Reconstitution: Handle alamandine as a small linear research peptide — see the peptide reconstitution guide and solubility and solvent selection guide.
- •Purity verification: Because alamandine differs from angiotensin-(1-7) by a single residue, identity confirmation is critical — verify by HPLC and mass spectrometry; review peptide purity testing methods and how to read a certificate of analysis.
- •Assay design: Pair alamandine with MrgD-selective antagonists and MrgD-null controls; run angiotensin-(1-7) in parallel to separate MrgD from Mas effects; account for possible interconversion within the peptide cascade.
- •Stability: As a short peptide, alamandine is subject to peptidase activity in biological matrices; use appropriate protease inhibitors and cold-chain handling for in vitro work.
Related RAS and GPCR Research
Alamandine is best interpreted within the renin-angiotensin system and the wider vasoactive-peptide literature. Researchers cross-reference adjacent systems profiled on Peptides.SO:
- •Angiotensin-(1-7) (ACE2 / Mas axis) — the closest sibling peptide and primary matched comparator.
- •Angiotensin II (AT1R / AT2R / RAAS) — the classical, opposing arm of the system.
- •Bradykinin (kallikrein-kinin system) — a parallel vasoactive-peptide axis frequently studied alongside RAS.
To compare research reagents and suppliers, use the Peptides.SO supplier comparison tools and the how to evaluate peptide suppliers guide.
Frequently Asked Research Questions
What receptor does alamandine target?
Alamandine signals through MrgD (MrgprD), a class A GPCR distinct from the Mas receptor used by angiotensin-(1-7). MrgD assignment is the defining pharmacological feature of alamandine, supported by receptor loss-of-function studies (Physiol Rep, 2026).
How does alamandine differ from angiotensin-(1-7)?
By a single N-terminal residue (alanine instead of aspartate). This minimal change reroutes the peptide from the Mas receptor to MrgD, making the two peptides a matched pair for distinguishing the two protective RAS receptors (Biomedicines, 2025).
How is alamandine generated?
Through decarboxylation of angiotensin-(1-7), or via angiotensin A followed by ACE2 cleavage. The cascade continues to be characterized — alamandine-(1-5) was recently identified as a further component (Circ Res, 2026).
What research models use it?
Preclinical models spanning vascular calcification, cardiac fibrosis, retinal neovascularization, and bone resorption have employed alamandine as an MrgD-axis probe (Atherosclerosis, 2025; Cardiovasc Drugs Ther, 2025; J Zhejiang Univ Sci B, 2025; Calcif Tissue Int, 2026).
Summary
Alamandine is an endogenous heptapeptide of the alternative renin-angiotensin system that signals through the MrgD receptor, distinguishing it from its near-twin angiotensin-(1-7), which uses the Mas receptor. Its single-residue difference, distinct receptor, and protective-axis physiology make it a valuable laboratory reagent for dissecting RAS receptor pharmacology — best studied with MrgD-selective controls and angiotensin-(1-7) run in parallel. As with all compounds profiled on Peptides.SO, alamandine is presented for research use only, with no human, veterinary, therapeutic, or dosing application implied.
---
This article is provided for informational and research purposes only. Alamandine is a research reagent intended for laboratory use only and is not approved for human or veterinary use in this context. Always follow institutional safety and compliance requirements.